Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project
- PMID: 29714515
- PMCID: PMC5933599
- DOI: 10.1177/2168479017716715
Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project
Abstract
Background: While patient groups, regulators, and sponsors are increasingly considering engaging with patients in the design and conduct of clinical development programs, sponsors are often reluctant to go beyond pilot programs because of uncertainty in the return on investment. We developed an approach to estimate the financial value of patient engagement.
Methods: Expected net present value (ENPV) is a common technique that integrates the key business drivers of cost, time, revenue, and risk into a summary metric for project strategy and portfolio decisions. We assessed the impact of patient engagement on ENPV for a typical oncology development program entering phase 2 or phase 3.
Results: For a pre-phase 2 project, the cumulative impact of a patient engagement activity that avoids one protocol amendment and improves enrollment, adherence, and retention is an increase in net present value (NPV) of $62MM ($65MM for pre-phase 3) and an increase in ENPV of $35MM ($75MM for pre-phase 3). Compared with an investment of $100,000 in patient engagement, the NPV and ENPV increases can exceed 500-fold the investment. This ENPV increase is the equivalent of accelerating a pre-phase 2 product launch by 2½ years (1½ years for pre-phase 3).
Conclusions: Risk-adjusted financial models can assess the impact of patient engagement. A combination of empirical data and subjective parameter estimates shows that engagement activities with the potential to avoid protocol amendments and/or improve enrollment, adherence, and retention may add considerable financial value. This approach can help sponsors assess patient engagement investment decisions.
Keywords: expected net present value; patient engagement; risk-adjusted financial model; therapeutic development.
Conflict of interest statement
Figures

Similar articles
-
Assessing the net financial benefits of employing digital endpoints in clinical trials.Clin Transl Sci. 2024 Aug;17(8):e13902. doi: 10.1111/cts.13902. Clin Transl Sci. 2024. PMID: 39072949 Free PMC article.
-
Assessing the Financial Value of Decentralized Clinical Trials.Ther Innov Regul Sci. 2023 Mar;57(2):209-219. doi: 10.1007/s43441-022-00454-5. Epub 2022 Sep 14. Ther Innov Regul Sci. 2023. PMID: 36104654 Free PMC article.
-
Impact of summer programmes on the outcomes of disadvantaged or 'at risk' young people: A systematic review.Campbell Syst Rev. 2024 Jun 13;20(2):e1406. doi: 10.1002/cl2.1406. eCollection 2024 Jun. Campbell Syst Rev. 2024. PMID: 38873396 Free PMC article. Review.
-
Patient Engagement Partnerships in Clinical Trials: Development of Patient Partner and Investigator Decision Aids.Patient. 2020 Dec;13(6):745-756. doi: 10.1007/s40271-020-00460-5. Epub 2020 Oct 7. Patient. 2020. PMID: 33026639 Free PMC article.
-
Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research.J Alzheimers Dis. 2018;62(3):1079-1090. doi: 10.3233/JAD-170866. J Alzheimers Dis. 2018. PMID: 29562541 Free PMC article. Review.
Cited by
-
Commentary: an industry perspective on the importance of incorporating participant voice before, during, and after clinical trials.Trials. 2022 Nov 28;23(1):966. doi: 10.1186/s13063-022-06905-6. Trials. 2022. PMID: 36443805 Free PMC article.
-
Delivering Digital Health Solutions that Patients Need: A Call to Action.Ther Innov Regul Sci. 2024 Mar;58(2):236-241. doi: 10.1007/s43441-023-00592-4. Epub 2023 Dec 11. Ther Innov Regul Sci. 2024. PMID: 38082118 Free PMC article.
-
Frameworks for supporting patient and public involvement in research: Systematic review and co-design pilot.Health Expect. 2019 Aug;22(4):785-801. doi: 10.1111/hex.12888. Epub 2019 Apr 22. Health Expect. 2019. PMID: 31012259 Free PMC article.
-
Patient and Public Engagement in Integrated Knowledge Translation Research: Are we there yet?Res Involv Engagem. 2019 Feb 12;5:8. doi: 10.1186/s40900-019-0139-1. eCollection 2019. Res Involv Engagem. 2019. PMID: 30805202 Free PMC article.
-
Tailored physical activity behavior change interventions: challenges and opportunities.Transl Behav Med. 2021 Dec 14;11(12):2174-2181. doi: 10.1093/tbm/ibab106. Transl Behav Med. 2021. PMID: 34424344 Free PMC article. Review.
References
-
- Anderson M, McCleary KK. On the path to a science of patient input. Sci Transl Med. 2016;8. - PubMed
-
- Clinical Trials Transformation Initiative. CTTI recommendations: effective engagement with patient groups around clinical trials. https://www.ctti-clinicaltrials.org/files/pgctrecs.pdf. Accessed November 29, 2016.
-
- Getz KA. Establishing return-on-investment expectations for patient-centric initiatives. Therapeutic Innovation & Regulatory Science. 2015;49:745–749. - PubMed
-
- Hunter NL, O’Callaghan KM, Califf RM. Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA. 2015:1–3. - PubMed
-
- Medical Device Innovation Consortium. Patient centered benefit-risk assessment (PCBR). http://mdic.org/pcbr/ . Accessed February 2, 2016.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical